Lantheus Holdings Inc Earnings

The next earnings date for Lantheus Holdings Inc is October 30, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Lantheus Holdings Inc Earnings

Report DateEstimated Earnings Per Share
10/30/2025$1.67

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Lantheus Holdings Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/06/2025---$1.57-5.99%
04/30/2025Before Market$1.53-7.49%
02/20/2025Before Market$1.593.04%
11/06/2024Before Market$1.708.97%
07/31/2024Before Market$1.80-1.64%
05/02/2024Before Market$1.699.74%
02/22/2024Before Market$1.7520.69%
11/02/2023Before Market$1.4711.36%
08/03/2023Before Market$1.5417.56%
05/04/2023Before Market$1.4716.67%
02/23/2023Before Market$1.3742.71%
11/03/2022Before Market$0.9919.28%
08/04/2022Before Market$0.8927.14%
04/29/2022Before Market$0.97110.87%
02/24/2022Before Market$0.2547.06%
11/04/2021Before Market$0.0833.33%
07/28/2021Before Market$0.11120.00%
05/04/2021Before Market$0.05600.00%
02/25/2021After Market$0.07600.00%
11/05/2020Before Market$0.04300.00%
07/30/2020Before Market$0.1066.67%
04/30/2020Before Market$0.3633.33%
02/25/2020Before Market$0.3413.33%
10/31/2019Before Market$0.2833.33%
07/25/2019Before Market$0.270.00%
04/30/2019Before Market$0.2812.00%
02/19/2019After Market$0.2471.43%
10/30/2018After Market$0.2433.33%
08/01/2018After Market$0.2618.18%
05/02/2018After Market$0.220.00%
02/26/2018After Market$0.12-40.00%
11/02/2017After Market$0.2414.29%
08/01/2017After Market$0.3447.83%
05/02/2017After Market$0.2847.37%
02/21/2017After Market$0.1838.46%
11/01/2016After Market$0.15114.29%
08/04/2016After Market$0.24300.00%
05/03/2016After Market$0.15150.00%
02/22/2016After Market$0.13550.00%
11/04/2015After Market$0.18350.00%
08/04/2015After Market$0.05135.71%

More About Lantheus Holdings Inc

Country
USA
Full Time Employees
808

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Holdings Inc Earnings” Can Refer to the Lantheus Holdings Inc Earnings Date

Some people say “Lantheus Holdings Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Lantheus Holdings Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Lantheus Holdings Inc Stock on the Earnings Date

If you own Lantheus Holdings Inc stock (LNTH) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Lantheus Holdings Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Lantheus Holdings Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Lantheus Holdings Inc Earnings

You can contact us any time if you would like to ask questions about Lantheus Holdings Inc earnings or anything else related to the stock market.